A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
**Background/Objectives:** This article compares the effectiveness of baricitinib (BARI) 4 mg (oral, Janus kinase [JAK] 1/2 inhibitor) versus other targeted synthetic/biologic disease-modifying antirheumatic drugs, in combination with methotrexate (MTX), in moderate-to-severe rheumatoid arthritis pa...
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Columbia Data Analytics, LLC
2020-04-01
|
| Reeks: | Journal of Health Economics and Outcomes Research |
| Online toegang: | https://doi.org/10.36469/jheor.2020.12273 |